Who is sponsoring NCT03528967?

NCT03528967 is sponsored by Les Laboratoires des Médicaments Stériles.

What drugs are being tested in NCT03528967?

Interventions in NCT03528967: Enoxaparin 40 mg / 0.4 mL Prefilled Syringe, Aspirin 100 mg Oral Tablet, Enteric Coated.

What condition does NCT03528967 study?

NCT03528967 studies Placental Insufficiency, Enoxaparin.

Is NCT03528967 still recruiting?

NCT03528967 is currently completed. Last updated 2 July 2020.

Last reviewed 2020-07-02 · How we verify

NCT03528967: PRESANCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women

Completed Phase 4 Last updated 2 July 2020

What this trial tests

Phase 4 trial testing Enoxaparin 40 mg / 0.4 mL Prefilled Syringe in Placental Insufficiency in 89 participants. Completed in 31 July 2018.

Timeline

23 October 2013

Primary endpoint
31 July 2018

31 July 2018

Quick facts

Lead sponsor	Les Laboratoires des Médicaments Stériles
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	89
Start date	23 October 2013
Primary completion	31 July 2018
Estimated completion	31 July 2018
Sites	1 location across Tunisia

Drugs / interventions tested

Enoxaparin 40 mg / 0.4 mL Prefilled Syringe — full drug profile →
Aspirin 100 mg Oral Tablet, Enteric Coated — full drug profile →

Conditions studied

Placental Insufficiency — all drugs for Placental Insufficiency →
Enoxaparin — all drugs for Enoxaparin →

Sponsor

Les Laboratoires des Médicaments Stériles — full company profile →

Who can join

Adults 18 to 45, female only, with Placental Insufficiency or Enoxaparin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of the effectiveness of Enoxaparin, at a preventive dose, combined with Aspirin treatment versus Aspirin only treatment in reducing placental insufficiency in pregnant women.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Placental Insufficiency

Currently open trials in the same condition.

NCT05423665 — Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies · recruiting

Other Les Laboratoires des Médicaments Stériles trials

Trials by the same sponsor.

NCT06999551 — Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients. · Phase 4 · not yet recruiting
NCT06862726 — Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation · Phase 4 · enrolling by invitation
NCT06503965 — Tunisian Registry of Trans Catheter Aortic Valve Implantation · recruiting
NCT05603130 — Epidemiologic Register on Diabetes and COVID-19 in Tunisia · completed
NCT04607239 — The Impact of Telemonitoring in the Management of Hypertension · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03528967 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Les Laboratoires des Médicaments Stériles
Last refreshed: 2 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03528967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing